Our pipeline reflects our strategic focus as well as our scientific and novel cGMP manufacturing, regulatory capabilities. We are committed to advancing these candidates through clinical development to deliver new hope to patients cost effectively.
| Therapeutic Area | Product Candidate | Platform | Indication - Development Phase |
|---|---|---|---|
| Oncology | ABS-101 | Monoclonal Antibody | Solid / Liuid Tumors |
| Immunology | ABS-102 | Biosimilar | Autoimmune / Diabetology Disorders |
| Rare Disease | ABS-GT01 AAV | Gene Therapy | Genetic Disorder / Rare Diseases |
| Biologics | ABS-Universal Viral Vaccine | Novacell platform | infectious diseases |
ABSNovacell Biopharmaceuticals is pioneering the development of human vaccines that utilize NOVACELL Platform for both production and innovation. These vaccines are designed to address serious infectious diseases by leveraging the unique biological properties of egg embryo stem cells, which enable scalable manufacturing, advanced antigen presentation and enhanced immune response. The company’s approach incorporates state-of-the-art R&D and proprietary cell line technologies, focusing on global health threats such as pandemic and seasonal flu, as well as emerging viruses including Biowarfare threat.
ABSNovacell Biopharmaceuticals develops veterinary vaccines that serve the needs of major livestock and companion animals, including cattle, horses, birds, fish and household pets. These vaccines are produced using advanced biotechnological platforms such as mammalian, yeast, E. coli and insect cells, ensuring high standards of potency, safety and regulatory compliance. The company's focus on research innovation enables rapid response to emerging diseases like swine flu and bird flu, as well as the development of vaccines for seasonal threats and other critical pathogens that are transmissible to humans. We also develop specialty pharmaceuticals for dogs, cats, horses and cattle.
We are developing novel monoclonal antibodies, therapeutic proteins and high-fidelity biosimilars. Our work includes cell line development, process optimization and analytical characterization. These efforts aim to provide targeted, effective treatment options and increase market competition to improve access and affordability.
We are pioneering advanced therapies, including next-generation AAV vectors for gene delivery and editing. Our capabilities include vector design, editing, process science and manufacturing for complex modalities. We are licensing these platforms from global partners. These innovations aim to unlock one-time, potentially curative treatments for patients with limited options.
Stem cells are unique biological cells with the ability to self-renew and differentiate into various specialized cell types, making them essential for applications in regenerative medicine and biotechnology. In vaccine development and therapeutics, animal stem cells serve as versatile platforms that enable large-scale production of vaccines and biologics with enhanced immune response properties. They provide a sustainable and scalable source for generating cells and proteins required for immunization, thereby supporting more efficient and rapid biologics development.
Diagnostic kits are specialized medical tools designed to detect, diagnose and monitor diseases and health conditions by analyzing biological samples such as blood, urine, saliva, or swabs. These kits contain reagents and instructions to facilitate accurate testing, enabling healthcare providers to confirm disease presence, predict disease risk and guide treatment decisions. Diagnostic kits serve various purposes including identifying infectious agents, genetic abnormalities and biomarkers related to chronic diseases. The rise of at-home diagnostic kits has empowered individuals to conveniently perform health tests with rapid results, improving access to timely medical insights.
We provide a cost-effective alternative by making essential medications more accessible without compromising on quality, efficacy or safety. Generic drugs undergo rigorous regulatory scrutiny to ensure that they meet the same standards as branded medicines, including bioequivalence in absorption and action. Their availability promotes competition, reduces healthcare costs and increases treatment options for patients worldwide. Through generics, healthcare systems can allocate resources more efficiently, enabling wider access to vital therapies while maintaining high standards of patient care.
We Specialize in a wide range of products and services under the professional management with Global Multi-National Biopharmaceutical expertise and hands-on experience.
Our experience includes Quality and Regulatory compliance, guidelines with cGMP, cGLP, cGCP, ICH, USP, EP and JP in Bacterial and Viral Vaccines, r-DNA derived Proteins, Monoclonal Antibodies and Cell Gene Therapy. We provide operational excellence, continuous manufacturing, OPEX, CAPEX, project management, operational LEAN SIX Sigma and Biostatistics.
Expertise in CMC and Non-clinical modules submissions for US-FDA, EMA, MHRA, WHO and DCGI expertise in guiding , authoring and submission of IND, NDA and BLA. Help 483's, warning letters, consent decrees, technical & financial due deligency and SOURCE funding.
For Specific projects Contact Us